BR0113291A - steres de aporfina e seu uso em terapia - Google Patents

steres de aporfina e seu uso em terapia

Info

Publication number
BR0113291A
BR0113291A BR0113291-1A BR0113291A BR0113291A BR 0113291 A BR0113291 A BR 0113291A BR 0113291 A BR0113291 A BR 0113291A BR 0113291 A BR0113291 A BR 0113291A
Authority
BR
Brazil
Prior art keywords
therapy
derivatives
aporphine
parkinson
disease
Prior art date
Application number
BR0113291-1A
Other languages
English (en)
Inventor
Hakan Wikstrom
Durk Dijkstra
Thomas Cremers
Per Erik Andren
Sandrine Marchais
Ulrik Jurva
Original Assignee
Axon Biochemicals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Biochemicals Bv filed Critical Axon Biochemicals Bv
Publication of BR0113291A publication Critical patent/BR0113291A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

"éSTERES DE APORFINA E SEU USO EM TERAPIA". São descritos novos derivados de aporfina que têm a fórmula (1) e seus sais fisiologicamente aceitáveis. Os ditos derivados podem ser usados para o tratamento de doença de Parkinson, hemicrania, síndrome das pernas inquietas (RLS), disfunção sexual em homens e mulheres, hiperprolactemia e distúrbios psicóticos e/ou avaliação da doença de Parkinson. Processos para a preparação de tais derivados são também descritos.
BR0113291-1A 2000-08-17 2001-07-20 steres de aporfina e seu uso em terapia BR0113291A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002934A SE0002934D0 (sv) 2000-08-17 2000-08-17 New aporphine esters and in their use in therapy
PCT/SE2001/001658 WO2002014279A1 (en) 2000-08-17 2001-07-20 New aporphine esters and their use in therapy

Publications (1)

Publication Number Publication Date
BR0113291A true BR0113291A (pt) 2004-01-06

Family

ID=20280719

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113291-1A BR0113291A (pt) 2000-08-17 2001-07-20 steres de aporfina e seu uso em terapia

Country Status (19)

Country Link
US (3) US7238705B2 (pt)
EP (1) EP1309553A1 (pt)
JP (1) JP2004506041A (pt)
KR (1) KR100865503B1 (pt)
CN (1) CN1242991C (pt)
AU (2) AU7122801A (pt)
BR (1) BR0113291A (pt)
CA (1) CA2419842C (pt)
CZ (1) CZ2003454A3 (pt)
EA (1) EA006388B1 (pt)
HU (1) HUP0301685A3 (pt)
IL (2) IL154096A0 (pt)
MX (1) MXPA03001465A (pt)
NO (1) NO324409B1 (pt)
NZ (1) NZ523893A (pt)
PL (1) PL360089A1 (pt)
SE (1) SE0002934D0 (pt)
WO (1) WO2002014279A1 (pt)
ZA (1) ZA200300828B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
AU2003242227A1 (en) * 2003-06-19 2005-01-04 Lotus Pharmaceutical Co., Ltd. Aporphine and oxoaporphine and the medical use thereof
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
CA2562465A1 (en) 2004-04-13 2005-10-27 The Mclean Hospital Corporation R(-)-11-hydroxyaporphine derivatives and uses thereof
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB2463833B (en) * 2007-06-26 2012-02-08 Parkinson S Inst Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders
US8431591B2 (en) 2007-07-12 2013-04-30 The Mclean Hospital Corporation R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
ES2315203B1 (es) * 2007-09-11 2010-01-13 Universidade De Santiago De Compostela Uso de oxoisoaporfinas y sus derivados como inhibidores selectivos de la monoamino oxidasa a.
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
US8592424B2 (en) 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
EP2419508A4 (en) * 2009-04-17 2012-11-14 Somalabs Inc METHOD OF INDUCING REWARD RESPONSE BY MODULATION OF DOPAMINERGIC SYSTEMS IN THE CENTRAL NERVOUS SYSTEM
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
BR112013015204A2 (pt) 2010-12-16 2019-10-01 Arx Llc composição farmacêutica em forma de unidade de dosagem formulada para administração sublingual e uso da referida composição
CN103458911B (zh) * 2011-02-11 2016-02-24 密歇根大学董事会 肽组合物和用于治疗患者的方法
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
EP3314251A1 (en) 2015-06-24 2018-05-02 Koninklijke Philips N.V. Sweat monitoring apparatus and monitoring method
KR20200110671A (ko) * 2018-01-18 2020-09-24 레우코스 바이오테크 에스. 엘. 아포몰핀·팔미트산 공결정 고체 입자 결정질 형태
EP3781149A4 (en) * 2018-04-20 2022-03-16 The General Hospital Corporation ACETYLATED PRODRUGS FOR ADMINISTRATION ACROSS THE BLOOD-BRAIN BARRIER

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
AU3140577A (en) * 1976-12-13 1979-06-14 Sterling Drug Inc N-propylnorapormorphine diesters
DE2717001C2 (de) * 1977-04-18 1984-06-20 Karl O. Helm Ag, 2000 Hamburg Arzneimittel mit antithrombotischer Wirkung
EP0040074B1 (en) * 1980-05-08 1985-07-31 Northeastern University N-substituted aporphines, a method of inducing emesis and a method of controlling psychosis utilising the same
US4353912A (en) * 1980-05-08 1982-10-12 Northeastern University N-Haloalkyl nor apomorphines and method of inactivating dopamine receptor sites and enhancing dopaminergic activity therewith
WO1990012574A1 (en) * 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
EP1175206A1 (en) * 1999-05-13 2002-01-30 Unihart Corporation Pharmaceutical compositions comprising apocodeine and/or its derivatives
IL151614A0 (en) * 2000-04-07 2003-04-10 Tap Holdings Inc Apomorphine derivatives and methods for their use
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
EP1950203A1 (en) 2007-01-24 2008-07-30 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds with ACAT, their preparation and use as medicaments

Also Published As

Publication number Publication date
WO2002014279A1 (en) 2002-02-21
IL154096A (en) 2009-11-18
CN1447792A (zh) 2003-10-08
NO324409B1 (no) 2007-10-08
HUP0301685A3 (en) 2010-03-29
EA006388B1 (ru) 2005-12-29
US7238705B2 (en) 2007-07-03
NO20030677D0 (no) 2003-02-11
CA2419842C (en) 2011-10-18
AU7122801A (en) 2002-02-25
NO20030677L (no) 2003-03-05
US20080119504A1 (en) 2008-05-22
KR100865503B1 (ko) 2008-10-28
SE0002934D0 (sv) 2000-08-17
EP1309553A1 (en) 2003-05-14
US20040018956A1 (en) 2004-01-29
EA200300266A1 (ru) 2003-08-28
US20050143408A1 (en) 2005-06-30
KR20030036703A (ko) 2003-05-09
AU2001271228B2 (en) 2006-02-02
CA2419842A1 (en) 2002-02-21
US7332503B2 (en) 2008-02-19
MXPA03001465A (es) 2004-12-13
JP2004506041A (ja) 2004-02-26
IL154096A0 (en) 2003-07-31
PL360089A1 (en) 2004-09-06
CN1242991C (zh) 2006-02-22
ZA200300828B (en) 2004-05-17
HUP0301685A2 (hu) 2003-08-28
NZ523893A (en) 2003-10-31
CZ2003454A3 (cs) 2003-06-18

Similar Documents

Publication Publication Date Title
BR0113291A (pt) steres de aporfina e seu uso em terapia
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
BR0109272A (pt) Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
ATE340171T1 (de) Piperazinderivate zur behandlung bakterieller infektionen
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
BR0316169A (pt) Derivados de indolil pirazinona úteis para tratamento de distúrbios e doenças hiperproliferativos associados com angiogênese
AR031152A1 (es) Tratamientos nuevos para el sindrome de piernas inquietas
BR9712321A (pt) Aminotiofenocarboxamidas
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
ATE232396T1 (de) Oxydiertes thymosin beta 4
BR0312232A (pt) Inibidores de caspases e seus usos
SE0102036D0 (sv) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
DE60019162D1 (de) Zolmitriptanhaltige arzneizusammensetzungen
BR0011778A (pt) Tienopirimidinas
BR0111267A (pt) Cicloexilaminas bicìclicas e seu uso como antagonistas do receptor de nmda
ATE389655T1 (de) Pyrimidinderivate
SE9300971D0 (sv) Hudvaardskomposition
HK1058515A1 (en) Use of pamoic acid for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates.
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
SE0001916D0 (sv) Novel formulation
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
AR023199A1 (es) Solucion acuosa estable de em12, y procedimiento de preparacion de dicha solucion
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
DE60111553D1 (de) Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.